ClinicalTrials.gg
RecruitingNCT07330778Updated Jul 2, 2026

A Study of CDX-622 in Participants With Mild to Moderate Asthma

A Phase 1 interventional study of CDX-622 in Mild to Moderate Asthma, sponsored by Celldex Therapeutics. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by Celldex Therapeutics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,695 studies in Asthma with a site in United States — 135 open to participants now, 188 under way, 19 of them phase 3. Asthma · United States.

Planned enrollment
1,232nd of 1,353
12 · median 100
Started
2026
with 53 others
Phase 1
128 of 1,695
11 open now
Primary completion
2027-03
later than 68 of 183 live
Registered
1,640th of 1,695
by date

Among the 1,695 studies in Asthma with a site in United States, this one is the 1,232nd largest by planned enrollment of the 1,353 interventional ones that give a count, is one of 54 that started in 2026, is one of 128 in phase 1, reaches primary completion later than 68 of the 183 other live ones, and was the 1,640th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

135 of the 1,695 studies in Asthma with a site in United States are open now. Recruiting first, the newest first:

129 more — sign in →

All 135 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,695 studies in Asthma with a site in United States, or all of them as a file.
02

Study summary

This is a study to determine the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of CDX-622 in adults with mild to moderate asthma.

Read the detailed description

CDX-622 is a bispecific antibody that binds to stem cell factor (SCF) and thymic stromal lymphopoietin (TSLP). Eligible participants with mild to moderate asthma will receive a single dose of CDX-622 via IV infusion. Additional follow-up visits will be required through EOS (week 12).

03

Conditions studied

  • Mild to Moderate Asthma

Browse trials for

Keywords

  • Asthma
  • Mild to moderate
  • CDX-622
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Males and females, ≥ 18 years of age
  2. Diagnosis of mild to moderate asthma for at least 12 months
  3. Pre-bronchodilator (FEV1) ≥ 70% of predicted normal
  4. Airway reversibility ≥ 12% and 200 mL improvement in FEV1
  5. Both males and females of must agree to use during the study and for 150 days after treatment
  6. Willing and able to comply with all study requirements and procedures

Key Exclusion Criteria:

  1. Females who are pregnant or nursing
  2. Pulmonary disease other than asthma
  3. Systemic diseases with elevated eosinophils other than asthma
  4. Hospitalization for treatment of asthma in the past 12 months or required oral due to asthma within the past 6 months
  5. History of needing ventilator support due to asthma
  6. Current nasal polyps
  7. Severe or uncontrolled asthma
  8. History of smoking or vaping within the past 6 months
  9. Tuberculosis, or C virus, or
  10. Immunomodulating biologic therapies within the past 3 months for non-extended half-life biologics.
  11. Prior receipt of TSLP or KIT inhibitors such as tezepelumab or briquilimab

Additional protocol defined inclusion and exclusion criteria could apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    CDX-622

    Eligible participants will receive a single dose

    Drug: CDX-622

Interventions

  • DrugCDX-622

    Administered Intravenously

06

What researchers measure

Primary outcomes

  1. To evaluate the safety and tolerability profile of CDX-622 in adults with mild to moderate asthma.

    Occurrence and incidence of Treatment-Emergent Adverse Events (TEAE) and serious adverse events during the study.

    Time frame: Day 1 up to Day 85 (12 weeks)

Secondary outcomes

  1. Change from baseline in fractional exhaled nitric oxide (FeNO) through week 12.

    Pre-treatment and post-treatment FeNO levels will be measured at specified visits and analyzed to evaluate changes from baseline in airway inflammation.

    Time frame: Day 1 up to Day 85 (12 weeks)

  2. Change from baseline in absolute eosinophil count (AEC) through week 12.

    Pre-treatment and post treatment blood samples will be collected at specified visits and analyzed for changes in AEC.

    Time frame: Day 1 up to Day 85 (12 weeks)

  3. Change from baseline through week 12 in serum biomarkers.

    Pre-treatment and post-treatment blood samples will be collected at specified visits and analyzed for changes in TSLP- and SCF-related serum biomarkers.

    Time frame: Day 1 up to Day 85 (12 weeks)

  4. Pharmacokinetic (PK) evaluation from baseline through week 12.

    CDX-622 serum concentrations measured at specific visits.

    Time frame: Day 1 up to Day 85 (12 weeks)

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Mar 2027, 9 months after the start.

Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's planned 9 months is above that.

Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2025
First posted
Jan 9, 2026
StartActual
Jun 1, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07330778
Responsible party
Sponsor
First posted
Jan 9, 2026
Start date
Jun 1, 2026
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Jul 2, 2026

Study contacts

Celldex Therapeutics
Contact
clinicaltrials@celldex.com
844-723-9363

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion